A PHASE I/II STUDY OF INTRATUMORAL INJECTION OF IPILIMUMAB IN COMBINATION WITH LOCAL RADIATION IN MELANOMA, NON-HODGKIN LYMPHOMA AND COLORECTAL CARCINOMA

Trial Profile

A PHASE I/II STUDY OF INTRATUMORAL INJECTION OF IPILIMUMAB IN COMBINATION WITH LOCAL RADIATION IN MELANOMA, NON-HODGKIN LYMPHOMA AND COLORECTAL CARCINOMA

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Anaplastic large cell lymphoma; Burkitt's lymphoma; Colon cancer; Cutaneous B-cell lymphoma; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Diffuse lymphoma; Follicular lymphoma; Hairy cell leukaemia; Malignant melanoma; MALT lymphoma; Mantle-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Rectal cancer; Sezary syndrome; T-cell leukaemia; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jan 2017 Status changed from suspended to discontinued.
    • 20 Nov 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 30 Apr 2013 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top